Aimmune Therapeutics

Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Nestle SA

Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares more than doubled to start out the week after reports surfaced that the company would be acquired by Nestle Health Sciences, a subsidiary of the Nestle.

Are Aimmune Shareholders Getting Enough in the Buyout?

Nestlé is buying the maker of a peanut allergy drug for children for $2.6 billion as it deepens its focus into health care and nutrition.

Nestle is paying $2.6 billion for a company that treats peanut allergies

NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Aimmune Therapeutics, Inc. (NASDAQ: AIMT) and its board of directors concerning the proposed acquisition of the company by Nestlé S.A.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Aimmune Therapeutics, Inc.

Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment.
Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment.

Here’s why Nestlé is buying a peanut-allergy company for $2.6B

New York, New York--(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/62871_5167b93204a2486d_001full.jpgTo: All Persons or Entitie

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Aimmune Therapeutics, Inc. to Nestlé S.A.

Swiss food giant Nestle early Monday announced an agreement to buy Aimmune Therapeutics, the maker of the only approved drug to treat peanut allergies, for $2.6 billion. AIMT stock soared.

Nestle To Buy Peanut Allergy Treatment Maker Aimmune For $2.6 Billion

Nestle is gobbling up the peanut allergy drugmaker Aimmune Therapeutics for a cool $2.6 billion.

Why Aimmune Therapeutics Stock Is Soaring Today

The world’s largest consumer products company, Nestlé S.A., has agreed to acquire Aimmune Therapeutics Inc.

Nestle Adds Peanut Allergy Treatment to Its Portfolio

TAIPEI, Taiwan--(BUSINESS WIRE)--Oak Stone Limited have commented on Nestle after it announced its definitive agreement to purchase biopharma company Aimmune for $2.6 billion.

Oak Stone Limited Comments On Nestle As They Agree To Acquire Allergy Treatment Maker Aimmune For $2.6 Billion

Nestle (SWX: NESN) on Monday expressed plans of buying Aimmune Therapeutics for £1.95 billion. The Brisbane-based biopharmaceutical company is largely known for its peanut allergy treatment.

Nestle wishes to acquire Aimmune Therapeutics for £1.95 billion

SAN DIEGO, Aug. 31, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Aimmune Therapeutics, Inc.

(AIMT) Alert: Johnson Fistel Investigates Proposed Sale of Aimmune Therapeutics; Is $34.50 a Fair Price?

Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.

Nestle pays $2 billion to secure Aimmune's allergy treatment

Nestle S.A. (OTC: NSRGY) subsidiary Nestle Health Sciences (NHSc) is aquiring biopharma company Aimmune Therapeutics, Inc.

Aimmune Shares Surge 170% As Nestle Set To Acquire Company At $2.6B Enterprise Value

Nestle said on Thursday it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own, adding a potential blockbuster to its health science portfolio.

Nestle to buy Aimmune Therapeutics for $2.6 billion

This press release is also available in Français (pdf) and Deutsch (pdf)

Nestlé to acquire Aimmune Therapeutics

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Inc.

Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science

Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.

Could This Small-Cap Biotech Stock Make You Rich?

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Is this battered biotech stock now a good deal for investors?

Is Aimmune Therapeutics a Buy?

Aimmune Therapeutics Inc (NASDAQ: AIMT) shares, which recovered Monday following an earnings-induced sell-off Friday, are adding to the gains.

Why Shares of Aimmune Are Trading Higher While DBV Plunges

Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q2 2020 Results - Earnings Call Transcript

Aimmune Therapeutics (AIMT) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Aimmune Therapeutics (AIMT) Reports Q2 Loss, Misses Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights

Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

BRISBANE, Calif.--(BUSINESS WIRE)--Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA®     Published in The Lancet Child & Adolescent Health

News for Aimmune Therapeutics Stock (AIMT)